

## BREAST-PREDICT Showcase Symposium - Agenda

*Wednesday 17th October 2018, 9:30 - 16:50 UCD Conway Lecture Theatre*

*9:30 – 10:00 Registration and coffee*

**10:00 – 10:20 Welcome address and overview of BREAST-PREDICT, Irish Cancer Society's 1st Collaborative Cancer Research Centre**

Prof. William Gallagher, Director of the UCD Conway Institute, Director of BREAST-PREDICT and Chief Scientific Officer at OncoMark Ltd.

**10:20 – 11:00 Keynote: Beyond routine cancer registration: the role of clinical cancer registers in support of quality control and research**

Prof. Mats Lambe, Department of Medical Epidemiology and Biostatistics (MEB), Karolinska Institutet (Stockholm, Sweden)

**11:00 – 11:30 Drug repurposing for breast cancer: focus on aspirin, statins and vitamin D**

Prof. Kathleen Bennett, Division of Population Health Sciences, Royal College of Surgeons in Ireland and Health Research Board (HRB) Research Leader

*11:30 - 11:50 Coffee break*

**11:50 – 12:20 Overview of the breast cancer portfolio of Cancer Trials Ireland studies**

Dr. Verena Murphy, Translational Research Leader, Cancer Trials Ireland

**12:20 – 12:50 Mutant p53 as a New Target for the Treatment of Triple-Negative Breast Cancer?**

Prof. Joe Duffy, School of Medicine, University College Dublin and St Vincent's University Hospital

**12:50 – 13:20 BET Inhibition as a therapeutic strategy for Invasive Lobular Breast Cancer**

Prof. Darran O'Connor, Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland

*13:20 - 14:10 Lunch*

**14:10 – 14:35 Biomarkers of response to TCHL based neo-adjuvant treatment of HER2-positive breast cancer**

Dr. Alex Eustace, Research Lead for Molecular Therapeutics for Cancer in Ireland, The National Institute for Cellular Biotechnology, Dublin City University

**14:35 – 15:00 Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumours to Detect Novel Actionable Targets**

Dr. Damir Varešlija, Department of Surgery, Royal College of Surgeons in Ireland

**15:00 – 15:25 Targeting the PI3K pathway to overcome anti-Her2 therapy resistance in HER2-positive breast cancer**

Dr. Sinead Toomey, Lecturer, Royal College of Surgeons in Ireland

*15:25 – 15:35 Coffee break*

**15:35 – 16:50 PhD Showcase Session**

*Michelle Lowry*, Trinity College Dublin: Investigating the role of CAIX in the mechanisms of HER2-targeted drug resistance in breast cancer cells and extracellular vesicles

*Dr. Ben Doherty*, Royal College of Surgeons in Ireland: ADAM22 as a therapeutic target for endocrine resistant metastatic breast

*Amelia Smith*, Trinity College Dublin: Pharmacoepidemiological studies in breast and colorectal cancer; the association between statins and cancer outcomes

*Luis Martinez*, Systems Biology Ireland, University College Dublin: Interference of gene regulatory networks in breast cancer

*Dr. Lisa Dwane*, Royal College of Surgeons in Ireland: The role of USP11 in endocrine-driven breast cancer

**18:00 – 19:15: PUBLIC SEMINAR - Breast cancer - a growing global challenge?**

*Albert Theatre, Royal College of Surgeons in Ireland (123 St Stephen's Green, Dublin 2, York Street Entrance)*

**Guest speaker: Prof. Elisabete Weiderpass** - Professor of Cancer Epidemiology at University of Tromsø (Norway) & Karolinska Institutet (Sweden), Head of the Research Department at the Cancer Registry of Norway, and Leader of the Genetic Epidemiology group at Folkhälsan Research Centre at the University of Helsinki in Finland. Director of the International Agency for Research on Cancer (IARC), World Health Organization, from 1st January 2019 onwards.

\*\*\*End of Day 1\*\*\*

**Thursday 18th October 2018, 9:30 - 13:30 UCD Conway Lecture Theatre**

9:30 – 10:00 Registration and coffee

**10:00 – 10:40 Keynote: Dynamic epigenetic regulation: single cells can make the difference**

Prof. Pernette Verschure, The Swammerdam Institute for Life Sciences, University of Amsterdam (The Netherlands)

**10:40 – 11:10 TBC**

Prof. Adrian Bracken, Smurfit Institute of Genetics, Trinity College Dublin

**11:10 – 11:30 Translation of novel targeted therapeutic approaches for breast cancer to clinical trials**

Prof. John Crown, Professor and consultant medical oncologist at St. Vincent's University Hospital, Chief Medical Officer at OncoMark Ltd.

**11:30 – 11:50 Targeting PP2A with LB-100 in HER2-positive breast cancer. A novel approach to overcome acquired lapatinib resistance**

Dr. Neil Conlon, The National Institute for Cellular Biotechnology, Dublin City University

11:50 - 12:10 Coffee break

**12:10 – 12:40 How systems biology can accelerate drug target discovery and development**

Prof. Walter Kolch, Director of Systems Biology Ireland, University College Dublin

**12:40 – 13:20 Keynote: Multilevel molecular analyses in breast cancer: gauging inter- and intra-tumor heterogeneity and elucidating its role in treatment response**

Prof. Anne-Lise Børresen-Dale, Professor Emerita at the Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital and Institute for Clinical Medicine, Faculty of Medicine, University of Oslo (Norway)

**13:20 – 13:30 Conclusions**

Prof. William Gallagher, Director of the UCD Conway Institute, Director of BREAST-PREDICT and Chief Scientific Officer at OncoMark Ltd.

*13:30 Lunch*

*\*\*\*End of Day 2\*\*\**

---

*For any queries, please contact: [luciana.herda@ucd.ie](mailto:luciana.herda@ucd.ie)*

**Directions** to UCD Conway Institute of Biomolecular and Biomedical Research:

<https://www.ucd.ie/conway/aboutus/contactus/>